Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 4:01 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 29 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Severe Insulin Resistance Clear all

Conditions: Diabetes Mellitus, Type 1 Diabetes, Cardiovascular Diseases (CVD), Severe Albuminuria, Estimated Glomerular Filtration Rate (eGFR), Hypoglycemia (Diabetic), Vascular Calcification, Carotid-femoral Pulse Wave Velocity, Kidney Diseases
Interventions: Routine/prescribed exogenous insulin dose; Drug
Lead sponsor: Rachel Miller; Other
Eligibility: Not listed
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2029
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Major Depressive Disorder, Major Depressive Disorder w/ Psychotic Features, Metabolic Syndrome
Interventions: Not listed
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 85 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Depression, Major Depressive Disorder, Dysthymic Disorder, Depressive Symptoms, Type 2 Diabetes, PreDiabetes, Insulin Resistance
Interventions: Good Days Ahead (GDA), Problem Solving Treatment in Primary Care (PST-PC), Antidepressant Medications, Active Control; Behavioral · Drug · Other
Lead sponsor: Indiana University; Other
Eligibility: 18 Years and older
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Second or Third Degree Burns
Interventions: Fenofibrate, Sugar Pill; Drug
Lead sponsor: The University of Texas Medical Branch, Galveston; Other
Eligibility: 4 Years to 20 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: Galveston, Texas

Conditions: Schizophrenia, Schizophrenia and Related Disorders, Bipolar Disorder, Bipolar and Related Disorders, Major Depressive Disorder, Major Depression Severe, Ketogenic Dieting, Ketosis, Metabolic Disease, Metabolic Syndrome
Interventions: LCHF Ketogenic Diet, Diet-as-Usual (DAU); Other
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Psoriasis, Inflammation, Coronary Artery Disease, Cardiometabolic Syndrome
Interventions: Orticumab, Placebo; Drug
Lead sponsor: Abcentra; Industry
Eligibility: 30 Years and older
Enrollment: 77 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 13
States / cities: Scottsdale, Arizona • Santa Monica, California • Tustin, California + 9 more

Conditions: Sleep, Diabetes
Interventions: baseline study; Behavioral
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years to 20 Years
Enrollment: 5 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Type 2 Diabetes Mellitus, Obesity
Interventions: Roux-en-Y Gastric Bypass Surgery, Laparoscopic Adjustable Gastric Banding, Lifestyle Weight Loss Intervention; Procedure · Behavioral
Lead sponsor: University of Pittsburgh; Other
Eligibility: 25 Years to 55 Years
Enrollment: 69 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2028
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Insulin Receptor Mutation, Partial Lipodystrophy
Interventions: Pegvisomant; Drug
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 18 Years to 70 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Generalized Lipodystrophy
Interventions: mibavademab; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 2 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 2
States / cities: Bethesda, Maryland • Ann Arbor, Michigan

Conditions: Nutritional and Metabolic Diseases, Inflammation, Physiological Responses
Interventions: Placebo, 10G, 20G, 40G, Placebonofiber; Dietary Supplement
Lead sponsor: Clinical Nutrition Research Center, Illinois Institute of Technology; Industry
Eligibility: 18 Years and older
Enrollment: 29 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2015
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Obesity, Insulin Resistance, Diabetes
Interventions: Not listed
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 18 Years to 65 Years · Female only
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2004
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Burns
Interventions: Insulin, Stable Isotopes, Indocyanine Green; Drug
Lead sponsor: United States Army Institute of Surgical Research; Federal
Eligibility: 18 Years to 72 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 1
States / cities: Fort Sam Houston, Texas

Conditions: Depression, Major Depressive Disorder, Weight Gain, Obesity, Metabolic Syndrome
Interventions: Reduction of Ultra-processed foods; Behavioral
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 80 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Adrenal Gland Hyperfunction, Cardiovascular Disease, Involutional Depression
Interventions: Not listed
Lead sponsor: National Institute of Mental Health (NIMH); NIH
Eligibility: 21 Years to 55 Years
Enrollment: 160 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 1999 – 2007
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Diabetes Mellitus
Interventions: BIOD-531, Humalog Mix 75/25, Humulin R U-500; Drug
Lead sponsor: Biodel; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2014
U.S. locations: 1
States / cities: Chula Vista, California

Conditions: Morbid Obesity, Metabolic Syndrome, Type2 Diabetes, Insulin Resistance
Interventions: S.L.I.M.M.S. Procedure; Procedure
Lead sponsor: The N.E.W. Program; Other
Eligibility: 18 Years to 65 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 2
States / cities: Newport Beach, California • Tustin, California

Conditions: Severe Insulin Resistance
Interventions: Metreleptin; Drug
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 5 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2030
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Depression, Bipolar Disorder, Mood Disorders, Insulin Resistance, Depressive Disorder, Major, Depressive Disorder
Interventions: Not listed
Lead sponsor: Stanford University; Other
Eligibility: 20 Years to 65 Years
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2016
U.S. locations: 1
States / cities: Stanford, California

Conditions: Burn Injury
Interventions: EAA Supplementation + Exercise Training, Placebo + Exercise Training; Dietary Supplement
Lead sponsor: The University of Texas Medical Branch, Galveston; Other
Eligibility: 7 Years to 17 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 1
States / cities: Galveston, Texas

Conditions: Psoriasis, Metabolic Syndrome
Interventions: Not listed
Lead sponsor: Tufts Medical Center; Other
Eligibility: 10 Years to 17 Years
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Syndrome
Interventions: Leptin A-100; Drug
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: Not listed
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2002
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Diabetes Mellitus, Severe Insulin Resistance
Interventions: HR-pQCT scan; Device
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 6 Months to 120 Years
Enrollment: 1,200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 1976
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Type 2 Diabetes, Insulin Resistance
Interventions: U-500 Insulin delivered by Omnipod (disposable insulin pump); Drug
Lead sponsor: Mountain Diabetes and Endocrine Center; Other
Eligibility: 18 Years to 75 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Asheville, North Carolina

Search by objective public record fields.

Relationship Between Insulin Dose and Complications in Type 1 Diabetes

Risks for Insulin Resistance and Metabolic Syndrome Between Major Depressive Disorder (MDD) or MDD With Psychotic Features

eIMPACT-DM Pilot Trial: Depression Treatment to Reduce Diabetes Risk

Acute and Long-Term Outcome Investigations of Fenofibrate on Severely Burned Patients

Ketogenic Metabolic Therapy in Schizophrenia, Bipolar Disorder, Major Depressive Disorder: Deep Omic Profiling

A Proof-of-Activity Study With Orticumab in Subjects With Psoriasis and Cardiometabolic Risk Factors

Individual Differences in Diabetes Risk: Role of Slow WaveSleep

The TRIABETES - ARMMS-T2D Study: A Randomized Trial to Compare Surgical and Medical Treatments for Type 2 Diabetes

Study of Growth Hormone Inhibition Using Pegvisomant in Severe Insulin Resistance

A Study of the Safety of Mibavademab in Pediatric and Adult Participants Switching From Metreleptin to Mibavademab for the Treatment of Generalized Lipodystrophy (GLD)

A Study of Strawberries and Disease Risk

Insulin Resistance in Severely Obese Patients

Insulin on Post Burn Hypermetabolism

Diet and Depression

Heart Disease Risk Factors in Major Depression

BIOD-531 vs. Humalog Mix 75/25 vs. Humulin R U-500 Post-Meal Glucose Control in Patients With Severe Insulin Resistance

The S.L.I.M.M.S. Procedure for Severe Clinical Obesity

Effect of Metreleptin Therapy in the Treatment of Severe Insulin Resistance

Insulin Resistance in Patients With Major Depression

Amino Acid Supplementation in Recovery From Severe Burns

Peds Metabolic Syndrome in Psoriasis

Leptin to Treat Severe Insulin Resistance - Pilot Study

Genetic Studies of Insulin and Diabetes

U-500R Insulin In Type 2 Diabetes With Severe Insulin Resistance Via Omnipod